Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation

Seminars in Cancer Biology

Volumn 43, Issue , 2017, Pages 74-89

  Huber, Veronica ^a   Camisaschi, Chiara ^a   Berzi, Angela ^a   Ferro, Simona ^a   Lugini, Luana ^b   Triulzi, Tiziana ^a   Tuccitto, Alessandra ^a   Tagliabue, Elda ^a   Castelli, Chiara ^a   Rivoltini, Licia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Acidity; Cancer; Glycolysis; Hypoxia; Immune checkpoints; Immunity; Immunosurveillance; Immunotherapy; Lactate; Myeloid derived suppressor cells; pH; Regulatory T cells; Therapeutic antibodies; Tumor microenvironment

Indexed keywords

ANTIBODY; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DARATUMUMAB; DICHLOROACETIC ACID; DOXORUBICIN; ELOTUZUMAB; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; MONOCLONAL ANTIBODY; PANTOPRAZOLE; PROGRAMMED DEATH 1 RECEPTOR; ACID;

ACIDITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; APOPTOSIS; BONE MARROW CELL; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CELL FUNCTION; CELL METABOLISM; CELL PH; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG TARGETING; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; LYMPHOMA; MALIGNANT NEOPLASM; METABOLIC REGULATION; MOLECULAR MECHANICS; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; IMMUNOLOGY; METABOLISM; NEOPLASM; PH;

ACIDS; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASMS; TUMOR ESCAPE;

EID: 85015854004     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2017.03.001     Document Type: Review

References (176)

1. [1] Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454, 10.1056/NEJMoa1200690.
2. [2] Wolchok, J.D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11 (2010), 155–164, 10.1016/S1470-2045(09)70334-1.
3. [3] Mlecnik, B., Bindea, G., Angell, H.K., Maby, P., Angelova, M., Tougeron, D., et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44 (2016), 698–711, 10.1016/j.immuni.2016.02.025.
4. [4] Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74, 10.1126/science.aaa4971.
5. [5] Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10, 10.1016/j.immuni.2013.07.012.
6. [6] Smyth, M.J., Dunn, G.P., Schreiber, R.D., Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90 (2006), 1–50, 10.1016/S0065-2776(06)90001-7.
7. [7] Jago, C.B., Yates, J., Camara, N.O., Lechler, R.I., Lombardi, G., Differential expression of CTLA-4 among T cell subsets. Clin. Exp. Immunol. 136 (2004), 463–471, 10.1111/j.1365-3156.2004.01304.x.
8. [8] Blackburn, S.D., Shin, H., Haining, W.N., Zou, T., Workman, C.J., Polley, A., et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10 (2009), 29–37, 10.1038/ni.1679.
9. [9] Oleinika, K., Nibbs, R.J., Graham, G.J., Fraser, A.R., Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin. Exp. Immunol. 171 (2013), 36–45, 10.1111/j.1365-2249.2012.04657.x.
10. [10] Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 (2009), 162–174, 10.1038/nri2506.
11. [11] Galdiero, M.R., Bonavita, E., Barajon, I., Garlanda, C., Mantovani, A., Jaillon, S., Tumor associated macrophages and neutrophils in cancer. Immunobiology 218 (2013), 1402–1410, 10.1016/j.imbio.2013.06.003.
12. [12] Smith, H.A., Kang, Y., The metastasis-promoting roles of tumor-associated immune cells. J. Mol. Med. (Berl) 91 (2013), 411–429, 10.1007/s00109-013-1021-5.
13. [13] Gatenby, R.A., Gillies, R.J., Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 4 (2004), 891–899, 10.1038/nrc1478.
14. [14] Warburg, O., On the origin of cancer cells. Science 123 (1956), 309–314.
15. [15] Lu, H., Forbes, R.A., Verma, A., Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 277 (2002), 23111–23115, 10.1074/jbc.M202487200.
16. [16] Ivanov, S.V., Kuzmin, I., Wei, M.H., Pack, S., Geil, L., Johnson, B.E., et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 12596–12601.
17. [17] Semenza, G.L., Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003), 721–732, 10.1038/nrc1187.
18. [18] Ward, P.S., Thompson, C.B., Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21 (2012), 297–308, 10.1016/j.ccr.2012.02.014.
19. [19] Supuran, C.T., Carbonic anhydrase inhibitors. Bioorg. Med. Chem. Lett. 20 (2010), 3467–3474, 10.1016/j.bmcl.2010.05.009.
20. [20] Hinton, A., Bond, S., Forgac, M., V-ATPase functions in normal and disease processes. Pflugers Arch. 457 (2009), 589–598, 10.1007/s00424-007-0382-4.
21. [21] Barneaud-Rocca, D., Borgese, F., Guizouarn, H., Dual transport properties of anion exchanger 1: the same transmembrane segment is involved in anion exchange and in a cation leak. J. Biol. Chem. 286 (2011), 8909–8916, 10.1074/jbc.M110.166819.
22. [22] Pouyssegur, J., Mechta-Grigoriou, F., Redox regulation of the hypoxia-inducible factor. Biol. Chem. 387 (2006), 1337–1346, 10.1515/BC.2006.167.
23. [23] Amith, S.R., Fliegel, L., Regulation of the Na+/H+ exchanger (NHE1) in breast cancer metastasis. Cancer Res. 73 (2013), 1259–1264, 10.1158/0008-5472.CAN-12-4031.
24. [24] Neri, D., Supuran, C.T., Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov. 10 (2011), 767–777, 10.1038/nrd3554.
25. [25] Damaghi, M., Wojtkowiak, J.W., Gillies, R.J., pH sensing and regulation in cancer. Front. Physiol., 4, 2013, 370, 10.3389/fphys.2013.00370.
26. [26] Lardner, A., The effects of extracellular pH on immune function. J. Leukoc. Biol. 69 (2001), 522–530.
27. [27] Kareva, I., Hahnfeldt, P., The emerging hallmarks of metabolic reprogramming and immune evasion: distinct or linked?. Cancer Res. 73 (2013), 2737–2742, 10.1158/0008-5472.CAN-12-3696.
28. [28] Labiano, S., Palazon, A., Melero, I., Immune response regulation in the tumor microenvironment by hypoxia. Semin. Oncol. 42 (2015), 378–386, 10.1053/j.seminoncol.2015.02.009.
29. [29] Cubillos-Ruiz, J.R., Mohamed, E., Rodriguez, P.C., Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer. J. Immunother. Cancer, 5, 2017, 5, 10.1186/s40425-016-0203-4.
30. [30] Chouaib, S., Noman, M.Z., Kosmatopoulos, K., Curran, M.A., Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene 36:January (4) (2017), 439–445, 10.1038/onc.2016.225.
31. [31] Egners, A., Erdem, M., Cramer, T., The response of macrophages and neutrophils to hypoxia in the context of cancer and other inflammatory diseases. Mediators Inflamm., 2016, 2016, 2053646, 10.1155/2016/2053646.
32. [32] Lunt, S.Y., Vander Heiden, M.G., Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27 (2011), 441–464, 10.1146/annurev-cellbio-092910-154237.
33. [33] Chang, C.H., Curtis, J.D., Maggi, L.B. Jr, Faubert, B., Villarino, A.V., O'Sullivan, D., et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153 (2013), 1239–1251, 10.1016/j.cell.2013.05.016.
34. [34] Sukumar, M., Liu, J., Ji, Y., Subramanian, M., Crompton, J.G., Yu, Z., et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J. Clin. Invest. 123 (2013), 4479–4488, 10.1172/JCI69589.
35. [35] Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109 (2007), 3812–3819, 10.1182/blood-2006-07-035972.
36. [36] Merezhinskaya, N., Ogunwuyi, S.A., Mullick, F.G., Fishbein, W.N., Presence and localization of three lactic acid transporters (MCT1 −2, and −4) in separated human granulocytes, lymphocytes, and monocytes. J. Histochem. Cytochem. 52 (2004), 1483–1493, 10.1369/jhc.4A6306.2004.
37. [37] Murray, C.M., Hutchinson, R., Bantick, J.R., Belfield, G.P., Benjamin, A.D., Brazma, D., et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat. Chem. Biol. 1 (2005), 371–376.
38. [38] Bueno, V., Binet, I., Steger, U., Bundick, R., Ferguson, D., Murray, C., et al. The specific monocarboxylate transporter (MCT1) inhibitor AR-C117977, a novel immunosuppressant, prolongs allograft survival in the mouse. Transplantation 84 (2007), 1204–1207, 10.1097/01.tp.0000287543.91765.41.
39. [39] Ekberg, H., Qi, Z., Pahlman, C., Veress, B., Bundick, R.V., Craggs, R.I., et al. The specific monocarboxylate transporter-1 (MCT-1) inhibitor AR-C117977, induces donor-specific suppression, reducing acute and chronic allograft rejection in the rat. Transplantation 84 (2007), 1191–1199, 10.1097/01.tp.0000287541.53389.be.
40. [40] Bosticardo, M., Ariotti, S., Losana, G., Bernabei, P., Forni, G., Novelli, F., Biased activation of human T lymphocytes due to low extracellular pH is antagonized by B7/CD28 costimulation. Eur. J. Immunol. 31 (2001), 2829–2838, 10.1002/1521-4141(200109)31:9<2829:AID-IMMU2829>3.0.CO;2-U.
41. [41] Calcinotto, A., Filipazzi, P., Grioni, M., Iero, M., De Milito, A., Ricupito, A., et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 72 (2012), 2746–2756, 10.1158/0008-5472.CAN-11-1272.
42. [42] Nakagawa, Y., Negishi, Y., Shimizu, M., Takahashi, M., Ichikawa, M., Takahashi, H., Effects of extracellular pH and hypoxia on the function and development of antigen-specific cytotoxic T lymphocytes. Immunol. Lett. 167 (2015), 72–86, 10.1016/j.imlet.2015.07.003.
43. [43] Pilon-Thomas, S., Kodumudi, K.N., El-Kenawi, A.E., Russell, S., Weber, A.M., Luddy, K., et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 76 (2016), 1381–1390, 10.1158/0008-5472.CAN-15-1743.
44. [44] Brand, A., Singer, K., Koehl, G.E., Kolitzus, M., Schoenhammer, G., Thiel, A., et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24 (2016), 657–671, 10.1016/j.cmet.2016.08.011.
45. [45] Ishii, S., Kihara, Y., Shimizu, T., Identification of T cell death-associated gene 8 (TDAG8) as a novel acid sensing G-protein-coupled receptor. J. Biol. Chem. 280 (2005), 9083–9087, 10.1074/jbc.M407832200.
46. [46] Ihara, Y., Kihara, Y., Hamano, F., Yanagida, K., Morishita, Y., Kunita, A., et al. The G protein-coupled receptor T-cell death-associated gene 8 (TDAG8) facilitates tumor development by serving as an extracellular pH sensor. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 17309–17314, 10.1073/pnas.1001165107.
47. [47] Onozawa, Y., Fujita, Y., Kuwabara, H., Nagasaki, M., Komai, T., Oda, T., Activation of T cell death-associated gene 8 regulates the cytokine production of T cells and macrophages in vitro. Eur. J. Pharmacol. 683 (2012), 325–331, 10.1016/j.ejphar.2012.03.007.
48. [48] Aoki, H., Mogi, C., Okajima, F., Ionotropic and metabotropic proton-sensing receptors involved in airway inflammation in allergic asthma. Mediators Inflamm., 2014, 2014, 712962, 10.1155/2014/712962.
49. [49] Mendler, A.N., Hu, B., Prinz, P.U., Kreutz, M., Gottfried, E., Noessner, E., Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int. J. Cancer 131 (2012), 633–640, 10.1002/ijc.26410.
50. [50] Haas, R., Smith, J., Rocher-Ros, V., Nadkarni, S., Montero-Melendez, T., D'Acquisto, F., et al. Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions. PLoS Biol., 13, 2015, e1002202, 10.1371/journal.pbio.1002202.
51. [51] Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L.N., et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun., 6, 2015, 6692, 10.1038/ncomms7692.
52. [52] Ma, Y., Shurin, G.V., Peiyuan, Z., Shurin, M.R., Dendritic cells in the cancer microenvironment. J. Cancer 4 (2013), 36–44, 10.7150/jca.5046.
53. [53] Hargadon, K.M., Tumor-altered dendritic cell function: implications for antitumor immunity. Front. Immunol., 4, 2013, 192, 10.3389/fimmu.2013.00192.
54. [54] Shurin, M.R., Yurkovetsky, Z.R., Tourkova, I.L., Balkir, L., Shurin, G.V., Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int. J. Cancer 101 (2002), 61–68, 10.1002/ijc.10576.
55. [55] Liu, Q., Zhang, C., Sun, A., Zheng, Y., Wang, L., Cao, X., Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J. Immunol. 182 (2009), 6207–6216, 10.4049/jimmunol.0803926.
56. [56] Shurin, M.R., Naiditch, H., Zhong, H., Shurin, G.V., Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol. Ther. 11 (2011), 988–992.
57. [57] Michielsen, A.J., Hogan, A.E., Marry, J., Tosetto, M., Cox, F., Hyland, J.M., et al. Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS One, 6, 2011, e27944, 10.1371/journal.pone.0027944.
58. [58] Bharadwaj, U., Li, M., Zhang, R., Chen, C., Yao, Q., Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res. 67 (2007), 5479–5488, 10.1158/0008-5472.CAN-06-3963.
59. [59] Tran Janco, J.M., Lamichhane, P., Karyampudi, L., Knutson, K.L., Tumor-infiltrating dendritic cells in cancer pathogenesis. J. Immunol. 194 (2015), 2985–2991, 10.4049/jimmunol.1403134.
60. [60] Vermeulen, M., Giordano, M., Trevani, A.S., Sedlik, C., Gamberale, R., Fernández-Calotti, P., et al. Acidosis improves uptake of antigens and MHC class I-restricted presentation by dendritic cells. J. Immunol. 172 (2004), 3196–3204.
61. [61] Tong, J., Wu, W.N., Kong, X., Wu, P.F., Tian, L., Du, W., et al. Acid-sensing ion channels contribute to the effect of acidosis on the function of dendritic cells. J. Immunol. 186 (2011), 3686–3692, 10.4049/jimmunol.1001346.
62. [62] Gottfried, E., Kunz-Schughart, L.A., Ebner, S., Mueller-Klieser, W., Hoves, S., Andreesen, R., et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107 (2006), 2013–2021, 10.1182/blood-2005-05-1795.
63. [63] Nasi, A., Fekete, T., Krishnamurthy, A., Snowden, S., Rajnavölgyi, E., Catrina, A.I., et al. Dendritic cell reprogramming by endogenously produced lactic acid. J. Immunol. 191 (2013), 3090–3099, 10.4049/jimmunol.1300772.
64. [64] Chirasani, S.R., Leukel, P., Gottfried, E., Hochrein, J., Stadler, K., Neumann, B., et al. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model. Int. J. Cancer 132 (2013), 843–853, 10.1002/ijc.27712.
65. [65] Dong, H., Bullock, T.N., Metabolic influences that regulate dendritic cell function in tumors. Front. Immunol., 5, 2014, 24, 10.3389/fimmu.2014.00024.
66. [66] Krawczyk, C.M., Holowka, T., Sun, J., Blagih, J., Amiel, E., DeBerardinis, R.J., et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 115 (2010), 4742–4749, 10.1182/blood-2009-10-249540.
67. [67] Vivier, E., Tomasello, E., Baratin, M., Walzer, T., Ugolini, S., Functions of natural killer cells. Nat. Immunol. 9 (2008), 503–510, 10.1038/ni1582.
68. [68] Grégoire, C., Chasson, L., Luci, C., Tomasello, E., Geissmann, F., Vivier, E., et al. The trafficking of natural killer cells. Immunol. Rev. 220 (2007), 169–182, 10.1111/j.1600-065X.2007.00563.x.
69. [69] Fogler, W.E., Volker, K., McCormick, K.L., Watanabe, M., Ortaldo, J.R., Wiltrout, R.H., NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction. J. Immunol. 156 (1996), 4707–4714.
70. [70] Mandal, A., Viswanathan, C., Natural killer cells: in health and disease. Hematol. Oncol. Stem Cell Ther. 8 (2015), 47–55, 10.1016/j.hemonc.2014.11.006.
71. [71] Cooper, M.A., Fehniger, T.A., Caligiuri, M.A., The biology of human natural killer cell subsets. Trends Immunol. 22 (2001), 633–640.
72. [72] Anfossi, N., André, P., Guia, S., Falk, C.S., Roetynck, S., Stewart, C.A., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25 (2006), 331–342, 10.1016/j.immuni.2006.06.013.
73. [73] Ferlazzo, G., Munz, C., NK cell compartments and their activation by dendritic cells. J. Immunol. 172 (2004), 1333–1339.
74. [74] Imai, K., Matsuyama, S., Miyake, S., Suga, K., Nakachi, K., Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year followup study of a general population. Lancet 356 (2000), 1795–1799, 10.1016/S0140-6736(00)03231-1.
75. [75] Shevtsov, M., Multhoff, G., Immunological and translational aspects of NK cell-based antitumor immunotherapies. Front. Immunol., 7, 2016, 492, 10.3389/fimmu.2016.00492.
76. [76] Guillerey, C., Huntington, N.D., Smyth, M.J., Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17 (2016), 1025–1036, 10.1038/ni.3518.
77. [77] Husain, Z., Huang, Y., Seth, P., Sukhatme, V.P., Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J. Immunol. 191 (2013), 1486–1495, 10.4049/jimmunol.1202702.
78. [78] Islam, A., Li, S.S., Oykhman, P., Timm-McCann, M., Huston, S.M., Stack, D., et al. An acidic microenvironment increases NK cell killing of Cryptococcus neoformans and Cryptococcus gattii by enhancing perforin degranulation. PLoS Pathog., 9, 2013, e1003439, 10.1371/journal.ppat.1003439.
79. [79] Loeffler, D.A., Juneau, P.L., Heppner, G.H., Natural killer-cell activity under conditions reflective of tumor micro-environment. Int. J. Cancer 48 (1991), 895–899.
80. [80] Severin, T., Müller, B., Giese, G., Uhl, B., Wolf, B., Hauschildt, S., et al. pH-dependent LAK cell cytotoxicity. Tumour Biol. 15 (1994), 304–310.
81. [81] Fischer, B., Müller, B., Fischer, K.G., Baur, N., Kreutz, W., Acidic pH inhibits non-MHC-restricted killer cell functions. Clin. Immunol. 96 (2000), 252–263, 10.1006/clim.2000.4904.
82. [82] Fischer, B., Müller, B., Fisch, P., Kreutz, W., An acidic microenvironment inhibits antitumoral non-major histocompatibility complex-restricted cytotoxicity: implications for cancer immunotherapy. J. Immunother. 23 (2000), 196–207.
83. [83] Müller, B., Fischer, B., Kreutz, W., An acidic microenvironment impairs the generation of non-major histocompatibility complex-restricted killer cells. Immunology 99 (2000), 375–384.
84. [84] Crane, C.A., Austgen, K., Haberthur, K., Hofmann, C., Moyes, K.W., Avanesyan, L., et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 12823–12828, 10.1073/pnas.1413933111.
85. [85] Guerra, N., Tan, Y.X., Joncker, N.T., Choy, A., Gallardo, F., Xiong, N., et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28 (2008), 571–580, 10.1016/j.immuni.2008.02.016.
86. [86] Lotzova, E., Savary, C.A., Herbermar, R.B., Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J. Immunol., 138, 1987, 2718.
87. [87] Rocca, Y.S., Roberti, M.P., Arriaga, J.M., Amat, M., Bruno, L., Pampena, M.B., Huertas, E., et al. Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun. 19 (2013), 76–85, 10.1177/1753425912453187.
88. [88] De Milito, A., Fais, S., Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 1 (2005), 779–786, 10.2217/14796694.1.6.779.
89. [89] Fais, S., A nonmainstream approach against cancer. J. Enzyme Inhib. Med. Chem. 31 (2016), 882–889, 10.3109/14756366.2016.1156105.
90. [90] Luciani, F., Spada, M., De Milito, A., Molinari, A., Rivoltini, L., Montinaro, A., et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl. Cancer Inst. 96 (2004), 1702–1713, 10.1093/jnci/djh305.
91. [91] Lugini, L., Federici, C., Borghi, M., Azzarito, T., Marino, M.L., Cesolini, A., et al. Proton pump inhibitors while belonging to the same family of generic drugs show different antitumor effect. J. Enzyme Inhib. Med. Chem. 31 (2016), 538–545, 10.3109/14756366.2015.1046062.
92. [92] Spugnini, E.P., Baldi, A., Buglioni, S., Carocci, F., de Bazzichini, G.M., Betti, G., et al. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J. Transl. Med., 9, 2011, 221, 10.1186/1479-5876-9-221.
93. [93] Ferrari, S., Perut, F., Fagioli, F., Brach Del Prever, A., Meazza, C., Parafioriti, A., et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed. J. Transl. Med., 11, 2013, 268, 10.1186/1479-5876-11-268.
94. [94] De Milito, A., Canese, R., Marino, M.L., Borghi, M., Iero, M., Villa, A., et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int. J. Cancer 127 (2010), 207–219, 10.1002/ijc.25009.
95. [95] Pittari, G., Filippini, P., Gentilcore, G., Grivel, J.C., Rutella, S., Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies. Front. Immunol., 6, 2015, 230, 10.3389/fimmu.2015.00230.
96. [96] van de Donk, N.W., Moreau, P., Plesner, T., Palumbo, A., Gay, F., Laubach, J.P., et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127 (2016), 681–695, 10.1182/blood-2015-10-646810.
97. [97] Bronte, V., Brandau, S., Chen, S.H., Colombo, M.P., Frey, A.B., Greten, T.F., et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun., 7, 2016, 12150, 10.1038/ncomms12150.
98. [98] Franklin, R.A., Liao, W., Sarkar, A., Kim, M.V., Bivona, M.R., Liu, K., et al. The cellular and molecular origin of tumor-associated macrophages. Science 344 (2014), 921–925, 10.1126/science.1252510.
99. [99] Miettinen, J.A., Salonen, R.J., Ylitalo, K., Niemelä, M., Kervinen, K., Säily, M., et al. The effect of bone marrow microenvironment on the functional properties of the therapeutic bone marrow-derived cells in patients with acute myocardial infarction. J. Transl. Med., 10, 2012, 66, 10.1186/1479-5876-10-66.
100. [100] Serrano, C.V. Jr, Fraticelli, A., Paniccia, R., Teti, A., Noble, B., Corda, S., et al. pH dependence of neutrophil-endothelial cell adhesion and adhesion molecule expression. Am. J. Physiol. 271 (1996), C962–C970.
101. [101] Cao, T.M., Takatani, T., King, M.R., Effect of extracellular pH on selectin adhesion: theory and experiment. Biophys. J. 104 (2013), 292–299, 10.1016/j.bpj.2012.12.005.
102. [102] Bellocq, A., Suberville, S., Philippe, C., Bertrand, F., Perez, J., Fouqueray, B., et al. Low environmental pH is responsible for the induction of nitric-oxide synthase in macrophages: evidence for involvement of nuclear factor-kappaB activation. J. Biol. Chem. 273 (1998), 5086–5092.
103. [103] Martínez, D., Vermeulen, M., Trevani, A., Ceballos, A., Sabatté, J., Gamberale, R., et al. Extracellular acidosis induces neutrophil activation by a mechanism dependent on activation of phosphatidylinositol 3-kinase/Akt and ERK pathways. J. Immunol. 176 (2006), 1163–1171.
104. [104] Solito, S., Bronte, V., Mandruzzato, S., Antigen specificity of immune suppression by myeloid-derived suppressor cells. J. Leukoc. Biol. 90 (2011), 31–36, 10.1189/jlb.0111021.
105. [105] Umansky, V., Blattner, C., Gebhardt, C., Utikal, J., The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines (Basel), 4(4), 2016, 10.3390/vaccines4040036 pii: E36.
106. [106] Gupta, P., Singh, A., Gowda, P., Ghosh, S., Chatterjee, A., Sen, E., Lactate induced HIF-1α-PRMT1 cross talk affects MHC I expression in monocytes. Exp. Cell Res. 347 (2016), 293–300, 10.1016/j.yexcr.2016.08.008.
107. [107] Selleri, S., Bifsha, P., Civini, S., Pacelli, C., Dieng, M.M., Lemieux, W., et al. Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming. Oncotarget 7 (2016), 30193–30210, 10.18632/oncotarget.8623.
108. [108] Colegio, O.R., Chu, N.Q., Szabo, A.L., Chu, T., Rhebergen, A.M., Jairam, V., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513 (2014), 559–563, 10.1038/nature13490.
109. [109] Corzo, C.A., Condamine, T., Lu, L., Cotter, M.J., Youn, J.I., Cheng, P., et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207 (2010), 2439–2453, 10.1084/jem.20100587.
110. [110] Noman, M.Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211 (2014), 781–790, 10.1084/jem.20131916.
111. [111] Cramer, T., Yamanishi, Y., Clausen, B.E., Förster, I., Pawlinski, R., Mackman, N., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112 (2003), 645–657.
112. [112] Kumar, V., Cheng, P., Condamine, T., Mony, S., Languino, L.R., McCaffrey, J.C., et al. CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity 44 (2016), 303–315, 10.1016/j.immuni.2016.01.014.
113. [113] Katara, G.K., Jaiswal, M.K., Kulshrestha, A., Kolli, B., Gilman-Sachs, A., Beaman, K.D., Tumor-associated vacuolar ATPase subunit promotes tumorigenic characteristics in macrophages. Oncogene 33 (2014), 5649–5654, 10.1038/onc.2013.532.
114. [114] Marjuki, H., Gornitzky, A., Marathe, B.M., Ilyushina, N.A., Aldridge, J.R., Desai, G., et al. Influenza A virus-induced early activation of ERK and PI3K mediates V-ATPase-dependent intracellular pH change required for fusion. Cell. Microbiol. 13 (2011), 587–601, 10.1111/j.1462-5822.2010.01556.x.
115. [115] De Henau, O., Rausch, M., Winkler, D., Campesato, L.F., Liu, C., Cymerman, D.H., et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 539 (2016), 443–447, 10.1038/nature20554.
116. [116] Vishvakarma, N.K., Singh, S.M., Immunopotentiating effect of proton pump inhibitor pantoprazole in a lymphoma-bearing murine host: implication in antitumor activation of tumor-associated macrophages. Immunol. Lett. 134 (2010), 83–92, 10.1016/j.imlet.2010.09.002.
117. [117] Vishvakarma, N.K., Singh, S.M., Augmentation of myelopoiesis in a murine host bearing a T cell lymphoma following in vivo administration of proton pump inhibitor pantoprazole. Biochimie 93 (2011), 1786–1796, 10.1016/j.biochi.2011.06.022.
118. [118] Ohashi, T., Akazawa, T., Aoki, M., Kuze, B., Mizuta, K., Ito, Y., et al. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int. J. Cancer 133 (2013), 1107–1118, 10.1002/ijc.28114.
119. [119] de Vallière, C., Wang, Y., Eloranta, J.J., Vidal, S., Clay, I., Spalinger, M.R., et al. G protein-coupled pH-sensing receptor OGR1 is a regulator of intestinal inflammation. Inflamm. Bowel Dis. 21 (2015), 1269–1281, 10.1097/MIB.0000000000000375.
120. [120] Biswas, S.K., Metabolic reprogramming of immune cells in cancer progression. Immunity 43 (2015), 435–449, 10.1016/j.immuni.2015.09.001.
121. [121] Olson, B.M., McNeel, D.G., Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front. Oncol., 3, 2013, 109, 10.3389/fonc.2013.00109.
122. [122] Facciabene, A., Motz, G.T., Coukos, G., T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72 (2012), 2162–2171, 10.1158/0008-5472.CAN-11-3687.
123. [123] De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45 (2016), 1135–1147, 10.1016/j.immuni.2016.10.021.
124. [124] Kinoshita, H., Yashiro, M., Fukuoka, T., Hasegawa, T., Morisaki, T., Kasashima, H., et al. Diffuse-type gastric cancer cells switch their driver pathways from FGFR2 signaling to SDF1/CXCR4 axis in hypoxic tumor microenvironments. Carcinogenesis 36 (2015), 1511–1520, 10.1093/carcin/bgv134.
125. [125] Ren, L., Yu, Y., Wang, L., Zhu, Z., Lu, R., Yao, Z., Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer. Oncotarget 7 (2016), 75763–75773, 10.18632/oncotarget.12409.
126. [126] Facciabene, A., Peng, X., Hagemann, I.S., Balint, K., Barchetti, A., Wang, L.P., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475 (2011), 226–230, 10.1038/nature10169.
127. [127] Dang, E.V., Barbi, J., Yang, H.Y., Jinasena, D., Yu, H., Zheng, Y., et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146 (2011), 772–784, 10.1016/j.cell.2011.07.033.
128. [128] Bollinger, T., Gies, S., Naujoks, J., Feldhoff, L., Bollinger, A., Solbach, W., et al. HIF-1α- and hypoxia-dependent immune responses in human CD4 + CD25high T cells and T helper 17 cells. J. Leukoc. Biol. 96 (2014), 305–312, 10.1189/jlb.3A0813-426RR.
129. [129] Clambey, E.T., McNamee, E.N., Westrich, J.A., Glover, L.E., Campbell, E.L., Jedlicka, P., et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E2784–E2793, 10.1073/pnas.1202366109.
130. [130] Lee, J.H., Elly, C., Park, Y., Liu, Y.C., E3 Ubiquitin Ligase VHL regulates hypoxia-inducible factor-1α to maintain regulatory T cell stability and suppressive capacity. Immunity 42 (2015), 1062–1074, 10.1016/j.immuni.2015.05.016.
131. [131] Pollizzi, K.N., Powell, J.D., Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat. Rev. Immunol. 14 (2014), 435–446, 10.1038/nri3701.
132. [132] Deng, B., Zhu, J.M., Wang, Y., Liu, T.T., Ding, Y.B., Xiao, W.M., et al. Intratumor hypoxia promotes immune tolerance by inducing regulatory T cells via TGF-β1 in gastric cancer. PLoS One, 8, 2013, e63777, 10.1371/journal.pone.0063777.
133. [133] Esen, N., Katyshev, V., Serkin, Z., Katysheva, S., Dore-Duffy, P., Endogenous adaptation to low oxygen modulates T-cell regulatory pathways in EAE. J. Neuroinflammation, 13, 2016, 13, 10.1186/s12974-015-0407-4.
134. [134] Flück, K., Breves, G., Fandrey, J., Winning, S., Hypoxia-inducible factor 1 in dendritic cells is crucial for the activation of protective regulatory T cells in murine colitis. Mucosal Immunol. 9 (2016), 379–390, 10.1038/mi.2015.67.
135. [135] Mascanfroni, I.D., Takenaka, M.C., Yeste, A., Patel, B., Wu, Y., Kenison, J.E., et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat. Med. 21 (2015), 638–646, 10.1038/nm.3868.
136. [136] Gagliani, N., Magnani, C.F., Huber, S., Gianolini, M.E., Pala, M., Licona-Limon, P., et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat. Med. 19 (2013), 739–746, 10.1038/nm.3179.
137. [137] Mittelbrunn, M., Gutiérrez-Vázquez, C., Villarroya-Beltri, C., González, S., Sánchez-Cabo, F., González, M.Á., et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat. Commun., 2, 2011, 282, 10.1038/ncomms1285.
138. [138] Okoye, I.S., Coomes, S.M., Pelly, V.S., Czieso, S., Papayannopoulos, V., Tolmachova, T., et al. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity 41 (2014), 89–103, 10.1016/j.immuni.2014.05.019.
139. [139] King, H.W., Michael, M.Z., Gleadle, J.M., Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer, 12, 2012, 421, 10.1186/1471-2407-12-421.
140. [140] Parolini, I., Federici, C., Raggi, C., Lugini, L., Palleschi, S., De Milito, A., et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 284 (2009), 34211–34222, 10.1074/jbc.M109.041152.
141. [141] Pearce, E.L., Poffenberger, M.C., Chang, C.H., Jones, R.G., Fueling immunity: insights into metabolism and lymphocyte function. Science, 342, 2013, 1242454, 10.1126/science.1242454.
142. [142] Wang, R., Green, D.R., Metabolic reprogramming and metabolic dependency in T cells. Immunol. Rev. 249 (2012), 14–26, 10.1111/j.1600-065X.2012.01155.x.
143. [143] Herbel, C., Patsoukis, N., Bardhan, K., Seth, P., Weaver, J.D., Boussiotis, V.A., Clinical significance of T cell metabolic reprogramming in cancer. Clin. Transl. Med., 5, 2016, 29, 10.1186/s40169-016-0110-9.
144. [144] Galgani, M., De Rosa, V., La Cava, A., Matarese, G., Role of metabolism in the immunobiology of regulatory T cells. J. Immunol. 197 (2016), 2567–2575, 10.4049/jimmunol.1600242.
145. [145] Kugelberg, E., T cells: nutrients guide differentiation. Nat. Rev. Immunol., 15, 2015, 666, 10.1038/nri3923.
146. [146] Sukumar, M., Roychoudhuri, R., Restifo, N.P., Nutrient competition a new axis of tumor immunosuppression. Cell 162 (2015), 1206–1208, 10.1016/j.cell.2015.08.064.
147. [147] Röhrig, F., Schulze, A., The multifaceted roles of fatty acid synthesis in cancer. Nat. Rev. Cancer 16 (2016), 732–749, 10.1038/nrc.2016.89.
148. [148] Zeng, H., Chi, H., The interplay between regulatory T cells and metabolism in immune regulation. Oncoimmunology, 2, 2013, e26586, 10.4161/onci.26586.
149. [149] Michalek, R.D., Gerriets, V.A., Jacobs, S.R., Macintyre, A.N., MacIver, N.J., Mason, E.F., et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186 (2011), 3299–3303, 10.4049/jimmunol.1003613.
150. [150] Procaccini, C., Carbone, F., Di Silvestre, D., Brambilla, F., De Rosa, V., Galgani, M., et al. The proteomic landscape of human ex vivo regulatory and conventional T cells reveals specific metabolic requirements. Immunity 44 (2016), 406–421, 10.1016/j.immuni.2016.01.028.
151. [151] Fremd, C., Schuetz, F., Sohn, C., Beckhove, P., Domschke, C., B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology, 2, 2013, e25443, 10.4161/onci.25443.
152. [152] Scott, A.M., Wolchok, J.D., Old, L.J., Antibody therapy of cancer. Nat. Rev. Cancer 12 (2012), 278–287, 10.1038/nrc3236.
153. [153] Ayyar, B.V., Arora, S., O'Kennedy, R., Coming-of-age of antibodies in cancer therapeutics. Trends Pharmacol. Sci. 37 (2016), 1009–1028, 10.1016/j.tips.2016.09.005.
154. [154] Menon, S., Shin, S., Dy, G., Advances in cancer immunotherapy in solid tumors. Cancers (Basel), 8, 2016, 10.3390/cancers8120106 pii: E106.
155. [155] Cairns, R., Papandreou, I., Denko, N., Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res. 4 (2006), 61–70, 10.1158/1541-7786.MCR-06-0002.
156. [156] Barnhart, B.C., Quigley, M., The role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies. Immunol. Cell Biol., 3, 2017, 10.1038/icb.2016.121 [Epub ahead of print].
157. [157] Wang, W., Singh, S., Zeng, D.L., King, K., Nema, S., Antibody structure, instability, and formulation. J. Pharm. Sci. 96 (2007), 1–26, 10.1002/jps.20727.
158. [158] Latypov, R.F., Hogan, S., Lau, H., Gadgil, H., Liu, D., Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. J. Biol. Chem. 287 (2012), 1381–1396, 10.1074/jbc.M111.297697.
159. [159] Ishikawa, T., Ito, T., Endo, R., Nakagawa, K., Sawa, E., Wakamatsu, K., Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies. Biol. Pharm. Bull. 33 (2010), 1413–1417.
160. [160] Wang, T., Kumru, O.S., Yi, L., Wang, Y.J., Zhang, J., Kim, J.H., et al. Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment. J. Pharm. Sci. 102 (2013), 2520–2537, 10.1002/jps.23645.
161. [161] Nooren, I.M., Thornton, J.M., Diversity of protein–protein interactions. EMBO J. 22 (2003), 3486–3492, 10.1093/emboj/cdg359.
162. [162] Watanabe, H., Matsumaru, H., Ooishi, A., Feng, Y., Odahara, T., Suto, K., et al. Optimizing pH response of affinity between protein G and IgG Fc: how electrostatic modulations affect protein–protein interactions. J. Biol. Chem. 284 (2009), 12373–12383, 10.1074/jbc.M809236200.
163. [163] Bonvin, P., Venet, S., Fontaine, G., Ravn, U., Gueneau, F., Kosco-Vilbois, M., et al. De novo isolation of antibodies with pH-dependent binding properties. MAbs 7 (2015), 294–302, 10.1080/19420862.2015.1006993.
164. [164] Igawa, T., Ishii, S., Tachibana, T., Maeda, A., Higuchi, Y., Shimaoka, S., et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat. Biotechnol. 28 (2010), 1203–1207, 10.1038/nbt.1691.
165. [165] Böhme, I., Bosserhoff, A.K., Acidic tumor microenvironment in human melanoma. Pigment Cell Melanoma Res. 29 (2016), 508–523, 10.1111/pcmr.12495.
166. [166] Vinay, D.S., Ryan, E.P., Pawelec, G., Talib, W.H., Stagg, J., Elkord, E., et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 35:Suppl (2015), S185–S198, 10.1016/j.semcancer.2015.03.004.
167. [167] Wang, B.Y., Zhang, J., Wang, J.L., Sun, S., Wang, Z.H., Wang, L.P., et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J. Exp. Clin. Cancer Res., 34, 2015, 109, 10.1186/s13046-015-0194-x.
168. [168] Spugnini, E., Fais, S., Proton pump inhibition and cancer therapeutics: A specific tumor targeting or it is a phenomenon secondary to a systemic buffering?. Semin. Cancer Biol. 43 (2017), 111–118, 10.1016/j.semcancer.2017.01.003.
169. [169] Moriyama, Y., Patel, V., Ueda, I., Futai, M., Evidence for a common binding site for omeprazole and N- ethylmaleimide in subunit A of chromaffin granule vacuolar-type H(+)-ATPase. Biochem. Biophys. Res. Commun. 196 (1993), 699–706, 10.1006/bbrc.1993.2306.
170. [170] Sabolić, I., Brown, D., Verbavatz, J.M., Kleinman, J., H(+)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole. Am. J. Physiol. 266:6 Pt. 2 (1994), F868–77.
171. [171] Mattsson, J.P., Väänänen, K., Wallmark, B., Lorentzon, P., Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim. Biophys. Acta 1065 (1991), 261–268.
172. [172] Quélo, I., Jurdic, P., Differential regulation of the carbonic anhydrase II gene expression by hormonal nuclear receptors in monocytic cells: identification of the retinoic acid response element. Biochem. Biophys. Res. Commun. 271 (2000), 481–491, 10.1006/bbrc.2000.2654.
173. [173] Balza, E., Piccioli, P., Carta, S., Lavieri, R., Gattorno, M., Semino, C., et al. Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance. Cell. Death. Dis., 7, 2016, e2304, 10.1038/cddis.2016.218.
174. [174] Aldrich, L.N., Kuo, S.Y., Castoreno, A.B., Goel, G., Kuballa, P., Rees, M.G., et al. Discovery of a small-molecule probe for V-ATPase function. J. Am. Chem. Soc. 137 (2015), 5563–5568, 10.1021/jacs.5b02150.
175. [175] Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R.R., Hospers, G.A., van den Eertwegh, A.J., et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol. Immunother. 63 (2014), 449–458, 10.1007/s00262-014-1528-9.
176. [176] Diem, S., Kasenda, B., Spain, L., Martin-Liberal, J., Marconcini, R., Gore, M., et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br. J. Cancer 114 (2016), 256–261, 10.1038/bjc.2015.467.